Opioid rotation is the term given to a switch from one opioid drug to another. The aim is to achieve a better balance between analgesia and sideeffects. The keystone to the rationale behind opioid rotation is incomplete cross-tolerance.
Tolerance is the phenomenon whereby the dose of a drug needs to be increased to achieve the same effect. It is also described as a shift to the right in the dose-response curve. Selective tolerance describes stable analgesia accompanied by diminution of side-effects.
Tolerance is a complex phenomenon and there has been some controversy as to how often it occurs with systemic opioids in the clinical management of cancer pain.' While tolerance occurs to adverse effects of opioids, clinically relevant tolerance to the analgesic effects is thought to be uncommon.
Cross-tolerance describes the phenomenon of tolerance to one drug resulting in tolerance to another drug. Incomplete cross-tolerance may apply to wanted effects, e.g. analgesia, and unwanted effects, e.g. sedation, nausea, vomiting, dry mouth and constipation.
The benefit of a switch from one opioid to another opioid depends on cross-tolerance to the analgesic effects being less than cross-tolerance to the adverse effects.
There is clinical evidence that cross-tolerance occurs; the patient with prior exposure to opioids is less susceptible to significant opioid-initiation adverse effects. Incomplete cross-tolerance is evidenced in the patient who has a recurrence of the initiation side-effects of opioids after switching opioids. Subclinical or even clinical opioid withdrawal symptoms on switching from one opioid to another opioid also reflects incomplete cross-tolerance. At a cellular level the theories of incomplete crosstolerance are complex but include binding to different receptor subtypes and the use of different secondary messenger systems by different opioids.
The clinical advantage of opioid rotation lies in the possibility of incomplete cross-tolerance favouring analgesia more than adverse effects. The disadvantage is that the clinician cannot know in advance whether an opioid switch will increase analgesia more than adverse effects. In addition, the equianalgesic dose of the alternative opioid chosen may be uncertain: it will depend on the opioids being used, the individual patient, and the degree of cross-tolerance, as well as the nature of the pain. The patient in the higher dose range is potentially at greater risk of the equianalgesic dose being several-fold different than expected.
Evidence that tables of equianalgesic dose conversions differ from the clinical situation in opioid rotation comes from clinical observations. 2,3 Methadone has been used in opioid rotation, particularly in North America, but a further complication of a methadone switch is the emerging evidence for its NMDA (N-methyl-D-aspartate) antagonist activity.
Consideration of the place of opioid rotation in the management of cancer pain naturally leads to the concept of opioid responsiveness. One of the commonest reasons for switching opioids is poorly controlled pain with unacceptable adverse affects from the current opioid. It is believed that opioid responsiveness should not be judged on the analgesic response to one opioid and should only be assessed after a trial of at least one alternative opioid.
To avoid unnecessary complication in the management of cancer pain it is important to examine some basic clinical facts. Morphine appears to have no clinically relevant ceiling effect to analgesia; hence there is no specific point of pain relief or inadequate pain relief with morphine but a point when adverse effects mean further titration of morphine is not possible. Whether unacceptable adverse effects occur before adequate analgesia is achieved depends on patient, drug and pain-related factors. The anxious patient who uses morphine as an anxiolytic is likely to reach unacceptable adverse effects before adequate analgesia. Similarly the inexpert use of morphine, with inappropriately rapid titration, lack of attention to prevention and management of adverse effects and inadequate use of adjuvant analgesics will result in unacceptable adverse effects before adequate analgesia is reached. Some pains are less responsive to opioids than others. Neuropathic pain is commonly quoted as being opioid poorly-responsive, but there is substantial animal experimental evidence that neuropathic pain can be controlled by opioids. However, in the clinical situation large doses are often required and adverse effects may become unacceptable before analgesia is reached rather than there being any predetermined absence of opioidresponsiveness. 4 4 It is of some concern that several of the reports in the literature advocating opioid rotation, have done so on the basis of pain in the confused, agitated, and evidently opioid-toxic patient. A less complicated and more predictable approach would be to: review the clinical situation and pain syndrome; review adjuvant analgesics; decrease the opioid dose avoiding sustained release preparations; deal with the altered sensorium secondary to opioid toxicity using haloperidol; correct any contributing abnormal biochemistry; opioid toxic patients simply do not drink enough. At present none of the other strong opioid analgesics has been shown to have advantages which would make it preferable to morphine for routine use.
However there is evidence that a failure to respond to one opioid does not mean failure to respond to all opioids and opioid rotation may allow pain control to be achieved without disabling side-effects.~ 5 The most frequently used alternative opioids in the UK are fentanyl, methadone and phenazocine; oxycodone and hydromorphone are alternatives elsewhere. Methadone is a difficult drug to use for the nonspecialist; titration can be difficult and equianalgesic conversion can be complex. Fentanyl is an interesting drug and more precise information is awaited from clinical trials, however it is not suitable in the unstable pain syndrome. Phenazocine is a useful alternative to morphine, particularly if dysphoria exists, but it is not available outside the UK. It is important to remember that some of the alternatives to morphine are much more potent than morphine.
An active quest for safe, more efficient analgesia, with a better balance between analgesia and unwanted effects is our universal aim. Opioids, of which morphine is the most commonly used, are the mainstay of moderate to severe cancer pain management. Opioid responsiveness is a continuum which can be affected by many factors, but inappropriate assessment and prescribing can shift a patient to the less responsive end of the continuum. Basic reassessment should be a prerequisite before any thought is given to opioid rotation.
Opioid responsiveness should not always be based on one opioid and in some situations an opioid switch can result in a better balance between wanted and unwanted effects because of incomplete cross-tolerance. Opioid rotation will have a place in the management of a selected group of patients. We need to examine the pharmacodynamic effects of the different opioids in the clinical setting, but at present this information is lacking. Dr Marie Fallon, Beatson Oncology Centre, University of Glasgow, Western Infirmary, Glasgow, UK.
